Search

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Skin, Lung and Quality of Life I

Session Type: ACR Abstract Submission ACR/ARHP Poster Session B
Monday, November 13, 2006
Papers:
1130
Predicting 24 Month Pulmonary Function Test (PFTs) Modified Rodnan Skin Score (mRSS) and Functional Results from Baseline Measurements in the Cyclophosphamide (CYC) versus Placebo Trial of System Sclerosis (SSc) Alveolitis
1131
Azathioprine as Maintenance Therapy Iin Early Diffuse Systemic Sclerosis Patients Treated for 1-Year With Low Dose Cyclophosphamide Pulse Therapy
1132
Histopathologic Patterns and Survival in Systemic Sclerosis - Related Interstitial Lung Disease
1133
Utility of the Serum Procollagen Propeptides in the Assessment of Lung Involvement Secondary to Systemic Sclerosis
1134
Bronchoalveolar Lavage Cell Count in Systemic Sclerosis Patients: Correlation With Radiological and Functional Lung Worsening.
1135
Oral Cyclophosphamide for Scleroderma Lung Disease with Active Alveolitis- A Decision Model
1136
Development of the Scleroderma Gastrointestinal Tract 1.0 (SSc-GIT1.0) Quality of Life Instrument- Preliminary Report
1137
Gastrointestinal Symptoms, Perceived Functioning and Quality of Life Issues Correlate with Gastric Myoelectrical Activity in Systemic Sclerosis (SSc) Patients
1138
Topical Application of Autologous Bone Marrow-Derived Cultured Mesenchymal Stem Cells to Scleroderma Ulcers
1139
Efficacy and Safety of a Protocol-Based Treatment of Severe Early Diffuse Systemic Sclerosis (dSSc) Using Mycophenolate Mofetil (MMF) in Combination with Intravenous Methylprednisolone (IV MP) Pulses
1140
A Predictive Model of Skin Thickening in Early Diffuse Systemic Sclerosis is Antibody Dependent
1141
Myofibroblasts and Hyalinized Collagen as Markers of Skin Disease in Systemic Sclerosis
1142
Skin Ultrasound in Patients With Systemic Sclerosis With Short Disease Duration, And Its Relation to Skin Score and Development of Hand Function
1143
Ability of Anti-Centromere and Anti-Topoisomerase Antibodies to Distinguish Subsets of Skin Involvement in Systemic Sclerosis
1144
Ability of Commonly Used Outcome Measures to Distinguish Subsets of Skin Involvement in Systemic Sclerosis
1145
Validation of the Michigan Hand Outcomes Questionnaire (MHQ) in Systemic Sclerosis (SSc)
1146
Influences of Clinical Features of Systemic Sclerosis (SSc) on the Michigan Hand Questionnaire (MHQ)
1147
Development and Validation of a Mouth Handicap Scale in Systemic Sclerosis (MHISS)
1148
Nailfold Capillaroscopic Findings in Systemic Sclerosis and Raynaud Phenomenon in a Rheumatology Clinical Setting
1149
Impact of Ilness and Symptom Burden in Patients with Systemic Sclerosis
1150
Problems Faced by Scleroderma (SSc) Patients: The Scleroderma Concerns Questionnaire
1151
The Efficacy of Self-Administered Stretching for Finger Joint Motion in Patients with Systemic Sclerosis
1152
Anti-U3RNP Autoantibody in Systemic Sclerosis (SSc): Classification, Demographics, Clinical and Laboratory Features, Natural History and Survival in a Series of 110 Patients
1153
Disease Features, Disease Type, HLA Types, and Autoantibody Profile in 17 Multicase SSc Families
1154
Diverging T Cell Polarization Identifies Distinct Clinical Phenotypes in Systemic Sclerosis
See more of: ACR Abstract Submission ACR/ARHP Poster Session B

To see other sessions for this day, use the date buttons to the left.